Tenderwize
Retour à la recherche

Open House Originale Rabattverträge 2024-08 - Fluticason/Vilanterol

Techniker Krankenkasse·Hamburg, Germany·Deadline Sep 30, 2026 · 35 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-08 - Fluticason/Vilanterol (Wirkstoffkombination)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or volume is provided. The financial potential of the contract is unknown, complicating bid/no-bid d...

The contract ends automatically on patent expiry. If the patent expires early, the contract may be shorter than expecte...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Conclusion of discount contracts for the active ingredient combination Fluticason/Vilanterol
  • Contracts with uniform conditions, no individual negotiations
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse (TK) and other German health insurers to conclude discount contracts (Rabattverträge) for the active ingredient combination Fluticason/Vilanterol. The procedure is non-competitive: any eligible pharmaceutical entrepreneur can join at any time during the contract period (until 30 Sept 2026). No estimated value, no award criteria (all accepted). Eligibility focuses on being a pharmaceutical entrepreneur with proper marketing authorization. The notice clarifies this is not a public procurement subject to EU directives.

Risques

No estimated value or volume is provided. The financial potential of the contract is unknown, complicating bid/no-bid d...

The contract ends automatically on patent expiry. If the patent expires early, the contract may be shorter than expecte...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as per § 4 Abs. 18 AMG regarding the offered medicines
  • Must have a valid marketing authorization for the product in Germany/EU/EEA
  • No convictions for certain criminal or economic offenses (last 5 years for §123 GWB, last 3 years for §124 GWB)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; all eligible participants are accepted.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2024-08 - Fluticason/Vilanterol

Discount contracts for Fluticason/Vilanterol combination. Contract duration max 24 months from 01 Oct 2024, ending 30 Sept 2026. Joining possible anytime during the period. No exclusivity.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Sep 2024 - Sep 2026

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; all eligible participants are accepted.

Date limite

Deadline Sep 30, 2026

Détails de la procédure

Date de publication
30 Jul 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
461715-2024

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3